多西他赛联合顺铂治疗晚期非小细胞肺癌有效性和安全性的Meta分析

doi:10.3969/j.issn.1006-6233.2020.04.022

摘要
图/表
参考文献
相关文章 (11)

全文: PDF (1685 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨多西他赛与顺铂协同应用治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性,为临床治疗提供理论依据。方法:网络检索Cochrane图书馆、EMBase、PubMed、CBM、CNKI等数据库,搜索多西他赛与顺铂协同应用治疗晚期NSCLC的RCTs,时间均从创建至2019年9月。由2名研究员对所得RCTs资料整合、核对,采用RevMan5.2的软件分析。结果:本文共选入14篇RCTs,(1199例患者),其中治疗组611例,对照组588例。研究表明,有效性方面,对照组相比,多西他赛与顺铂组总有效率和临床获益率有显著性差异,总有效率RR(95%CI)为1.56(1.36,1.80);临床获益率RR(95%CI)为1.13(1.07,1.19);安全性方面,治疗组不良反应发生危险度显著低于对照组,白细胞降低、血小板减少、恶心呕吐及脱发方面均低于对照组,RR(95﹪CI)分别为0.69(0.57,0.83)、0.44(0.29,0.65)、0.54(0.40,0.73)、0.49(0.33,0.72)。结论:基于所选证据,在治疗晚期NSCLC方面,治疗组较对照组药物优秀。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	耿帅
	郭宏举

关键词 ：多西他赛, 顺铂, 晚期非小细胞肺癌, Meta分析

Abstract：Objective: To explore the efficacy and safety of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC), and to provide theoretical basis for clinical treatment. Methods: The databases such as Cochrane Library, EMBASE, PubMed, CBM, CNKI, etc. were searched on the Internet. The RCTs of docetaxel and cisplatin in the treatment of advanced NSCLC were searched from the establishment to September 2019. The data of RCTs were integrated and checked by two researchers and analyzed by Revman 5.2 software. Results: In this paper, 14 RCTs (1199 patients) were selected, including 611 in the treatment group and 588 in the control group. In terms of effectiveness, the total effective rate and clinical benefit rate of docetaxel and cisplatin group were significantly different, the total effective rate RR (95% CI) was 1.56 (1.36, 1.80); the clinical benefit rate RR (95% CI) was 1.13 (1.07, 1.19); in terms of safety, the risk of adverse reactions in the treatment group was significantly lower than that in the control group, with leukopenia and thrombocytopenia RR (95% CI) was 0.69 (0.57, 0.83), 0.44 (0.29, 0.65), 0.54 (0.40, 0.73), 0.49 (0.33, 0.72), respectively. Conclusion: Based on the selected evidence, the treatment group was superior to the control group in the treatment of advanced NSCLC.

Key words： Docetaxel Cisplatin Advanced non-small cell lung cancer Meta-analysis

基金资助:战略支援部队特色医学中心医药卫生基础研究探索课题,(编号:19ZX63);战略支援部队特色医学中心军事医学研究课题,(编号:19ZX17)

通讯作者: 郭宏举

引用本文:

耿帅, 郭宏举. 多西他赛联合顺铂治疗晚期非小细胞肺癌有效性和安全性的Meta分析[J]. 河北医学, 2020, 26(4): 620-625.
GENG Shuai, GUO Hongju. Meta Analysis of the Efficacy and Safety of Docetaxel Combined with Cisplatin for Advanced Non-small Cell Lung Cancer. HeBei Med, 2020, 26(4): 620-625.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.04.022 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I4/620

[1] Osmani L, Askin F, Gabrielson E, et al.Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma(NSCLC):Moving from targeted therapy to immunotherapy [J].Semin Cancer Biol,2015,2(1):103~109
[2] Higgins J, Green S.Cochrane Handboor for systematic reviews of interventions version 5.1.0[M].Updated March,2011,downloaded July 2011.
[3] 刘强.多西他赛联合顺铂对晚期非小细胞肺癌的治疗效果分析[J].基层医学论坛,2015,19(5):652~653.
[4] 梅晓雷.多西他赛联合顺铂方案治疗晚期非小细胞肺癌的临床疗效评价[J].实用临床医药杂志,2013,17(15):69~71.
[5] 宁琳琳,郑国宝,张建国.多西他赛联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的疗效分析[J].系统医学,2017,2(11):105~107,120.
[6] 宋海平,邱文生,徐建华,等.多西他赛联合顺铂一线治疗晚期非小细胞肺癌[J].中国肿瘤临床,2007,(7):388~390.
[7] 田月晖,马军.多西他赛联合顺铂治疗非小细胞肺癌临床观察[J].齐齐哈尔医学院学报,2012,33(14):1876~1877.
[8] 曾淦华,曾维伟.多西他赛联合顺铂治疗非小细胞肺癌临床疗效研究[J].实用心脑肺血管病杂志,2013,21(12):36~37.
[9] 李守波,高春民.多西他赛联合顺铂治疗晚期非小细胞肺癌42例[J].中国民族民间医药,2010,19(20):133.
[10] 刘淑娟,姚娟,王琪琪,等.多西他赛联合顺铂治疗晚期非小细胞肺癌的临床观察[J].现代肿瘤医学,2008,(1):53~55.
[11] 路阳.多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效评价[J].中国现代医生,2014,52(15):41~43.
[12] 徐轶.多西他赛联合顺铂治疗晚期非小细胞肺癌临床研究[J].中国现代药物应用,2010,4(7):26~28.
[13] 唐箭翎.多西他赛联合顺铂治疗中老年晚期非小细胞肺癌35例疗效评价[J].航空航天医药,2010,21(5):747~748.
[14] 郑志范.多西他赛与顺铂联合治疗晚期非小细胞肺癌的疗效观察[J].海峡药学,2013,25(5):191~192.
[15] 麻青.顺铂联合多西他赛治疗老年晚期非小细胞肺癌临床观察[J].临床合理用药杂志,2013,6(22):72~73.
[16] 岳望现.顺铂联合多西他赛治疗晚期非小细胞肺癌的临床疗效研究[J].临床医学研究与实践,2016,1(25):64~66.
[17] Reck M, Brahmer J, Bennett B, et al.Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057[J].Eur Cancer,2018,102:23~30.